News
We send the latest information from SMC Laboratories.
MOA demonstration #1 【microbiota】| MASH treatment and fibrosis prevention study targeting gut microbiota in STAM mice
Today, we would like to introduce a demonstration example of a drug efficacy evaluation test of a bacterial co…
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments tha…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop …
STAM™ mice study: demonstration of MSCs-based cell therapy study for the NASH treatment
We introduce an example of a drug evaluation study on the efficacy of cell therapy in the treatment of NASH us…
Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice
SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD D…
【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice
We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studi…
SMC will present study at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting
We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Disease…
SMC will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023)
We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Mon…